Table 4: The comparison of clinical courses and management between the subgroups.

Total (n = 103)E group (n = 15)Other group (n = 88)P

Use of inotropics, n (%)28 (27)2 (13)26 (30) 0.192
Use of IABP, n (%)12 (12)0 (0)12 (14) 0.128
Use of ACEI or ARB, n (%)57 (55)10 (67)47 (53)0.340
Use of beta blocker, n (%)21 (20)4 (27)17 (19) 0.514
Use of diuretic, n (%)40 (39)2 (13)38 (43) 0.028*
Temporal pacemaker, n (%)10 (10)0 (0)10 (11) 0.169
Cardioversion, n (%)6 (6)0 (0)6 (7) 0.297
ICU hospitalization, n (%)63 (61)5 (33)58 (66) 0.017*
ICU hospitalization (days)2.0 (0–5.0)1.0 (0–2.0)3.0 (0–6.5) 0.005*
Hospitalization (days)14.0 (7.0–28.0)3.0 (3.0–9.0)17.0 (8.0–32.0) 0.001*
In-hospital cardiac mortality, n (%)0 (0)0 (0)0 (0)
Cardiac mortality during followup, n (%)0 (0)0 (0)0 (0)
Mortality during followup, n (%)14 (14)0 (0)14 (16) 0.097
Recurrence, n (%)0 (0)0 (0)0 (0)

IABP: intra-aortic balloon pump; ACEI: angiotensin converting enzyme inhibitor; ARB: angiotensin receptor blocker; ICU: intensive care unit.
Presented as median (inter-quartile range).
*Significant finding.